BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
VNDA upcoming catalysts
Vanda Pharmaceuticals: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (2 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 2 FDA event(s). Subscribe to VNDA (.ics).
Drugs: Tradipitant, VQW-765
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-12 | PDUFA date (company-disclosed) | pending | Vanda Pharmaceuticals Inc. VNDA | imsidolimab | PDUFA December 12, 2026 - Vanda Pharmaceuticals Inc. (imsidolimab) |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Social Anxiety Disorder (SAD) | active not recruiting | 500 |
| 2026-12-01 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Nausea and Vomiting; Obesity | recruiting | 280 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-02-20 | FDA approval | approved | VANDA PHARMS INC VNDA | BYSANTI | Approved 2026-02-20: BYSANTI (NDA220358 ORIG1) |
| 2025-12-30 | FDA approval | approved | VANDA PHARMS INC VNDA | NEREUS | Approved 2025-12-30: NEREUS (NDA220152 ORIG1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | Hypertension; Uncontrolled Hypertension | recruiting | 240 |
| 2026-09-04 | P3 | Vanda Pharmaceuticals VNDA | NCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm; Chronobiology Disorders | completed | 43 |
| 2026-09 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | Dry Eye | recruiting | 160 |
| 2026-09 est. | P2 | Vanda Pharmaceuticals VNDA | NCT07065773 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | Onychomycosis of Toenail | active not recruiting | 50 |
| 2026-03-30 | P3 | Vanda Pharmaceuticals VNDA | NCT06836557 Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis | completed | 17 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.